Home Overview Press Room Blog Publications For Students about us
Search

About the Biotech & Pharma Industries & Human Biotechnology


The fast-growing biotech industry is playing a dominant role in shaping the development, marketing and use of human biotechnologies. Like the pharmaceutical industry, it profits by developing products aimed at treating disease and restoring health. Although some biotech products and activities are socially and ethically controversial, the industry as a whole tends to oppose public oversight and regulation.

This situation is complicated by increasingly blurred lines between private biotechnology companies and university researchers, between perceptions of serving the public interest and the profit imperatives of private enterprise, and between research and commercialization.

In recent decades, the US Congress has enacted policies that allow controversial patents (such as those on gene sequences and human tissues), and that encourage closer university-corporate relations. These policies have led to a rapid commercialization of biology and medicine, and to a significant number of university-based researchers with financial ties to private companies. Such arrangements allow them to maintain the appearance of serving the public interest while pursuing careers in the private sector.

Private industry is an important player in the development of human biotechnologies. But the lack of a financially independent counterweight like the one that public universities used to provide makes effective oversight and responsible regulation imperative. Given the impact of the biotech industry on public debate, public policy, and all of our lives, its interests must be transparent.



As China’s one-child policy ends, surrogacy services rise in the U.S.by Kevin SmithSan Gabriel Valley TribuneApril 30th, 2016“I’ve been contacted by 15 to 18 agencies out of China... 90 percent of them don’t have any patients. They’re just new agencies trying to make a buck."
With CRISPR in Humans On the Horizon, Will the Public Back Intellia?by Alex LashXconomyApril 29th, 2016Intellia and Editas both lack what so many biotech investors crave: data from human clinical trials. As they race to the clinic, it's hard to tell if either company will pay off.
Let people most affected by gene editing write CRISPR rulesby Jessica HamzelouNew ScientistApril 29th, 2016The US National Academies' committee on human gene editing held a discussion in Paris at the French National Academy of Medicine.
A Single $249 Test Analyzes 30 Cancer Genes. But Do You Need It?by Sarah ZhangWIREDApril 28th, 2016Color Genomics is marketing gene tests for 30 cancers, but doctors caution that our ability to sequence DNA has far outpaced our ability to understand what the results mean.
A DNA Sequencer in Every Pocketby Ed YongThe AtlanticApril 28th, 2016Oxford Nanopore Technologies, which severed financial ties with DNA sequencing monolith Illumina in 2013, is "desperately thinking of ways of bringing them down.” These include a USB-powered sequencer called the MinION.
Scientists solve CRISPR’s ‘Energizer bunny’ problemby Sharon BegleySTATApril 27th, 2016A new CRISPR system called "CORRECT" stopped Cas9 from cutting again and again, and allowed researchers to edit one but not both copies of a target gene.
Meet The New CEO Of The $22 Billion Genomics Company You've Never Heard Ofby Christine FarrFast CompanyApril 27th, 2016Gene-sequencing giant Illumina is expanding to direct-to-consumer tests and perhaps brand partnerships, says new CEO Francis deSouza.
Dwarfism, Chemical Limb Lengthening, and Informed Consentby Joseph StramondoInternational Journal of Feminist Approaches to Bioethics BlogApril 25th, 2016A California biotech company is testing a drug designed to "normalize" annual growth but not address health complications of dwarfism.
Inside the Hidden Global Supply Chain for Frozen Sperm, Eggs, and Embryosby Sarah ZhangWIREDApril 25th, 2016Ever-changing laws and attitudes, which vary not only country by country but within a country, can make transportation logistically difficult.
US moves to sell gene-edited mushrooms fuel doubts over British ban on GM importsby Robin McKieThe Guardian April 23rd, 2016The USDA approved CRISPR-modified crops, but a European regulatory committee's delays are dismaying some UK researchers.
Displaying 1-10 of 2312  
Next >> 
Last Page » 
« Show Complete List » 


ESPAÑOL | PORTUGUÊS | Русский

home | overview | blog | publications| about us | donate | newsletter | press room | privacy policy

CGS • 1122 University Ave, Suite 100, Berkeley, CA 94702 • • (p) 1.510.665.7760 • (F) 1.510.665.8760